Evaluation of the effects of urotensin ii and soluble epoxide hydrolase inhibitor on skin microvessel tone in healthy controls and heart failure patients

Cardiovascular Therapeutics

Volumn 30, Issue 5, 2012, Pages 295-300

  Tran, Lavinia ^a   Kompa, Andrew R ^a   Wang, Bing H ^a   Krum, Henry ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Iontophoresis; Soluble epoxide hydrolase; Urotensin II; Vasodilation

Indexed keywords

AUDA; EPOXIDE HYDROLASE; HYDROLASE INHIBITOR; UNCLASSIFIED DRUG; UROTENSIN II;

ADULT; ARTICLE; BLOOD VESSEL TONE; CARDIAC PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOREARM; HEART FAILURE; HUMAN; IONTOPHORESIS; LASER DOPPLER FLOWMETRY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN BLOOD VESSEL;

ACETYLCHOLINE; ADAMANTANE; AGED; CAPILLARIES; ENZYME INHIBITORS; EPOXIDE HYDROLASES; FEMALE; HEART FAILURE; HUMANS; IONTOPHORESIS; LASER-DOPPLER FLOWMETRY; LAURIC ACIDS; MALE; MICROCIRCULATION; MIDDLE AGED; MUSCLE TONUS; MUSCLE, SMOOTH, VASCULAR; NITROPRUSSIDE; NOREPINEPHRINE; SAMPLE SIZE; SKIN; UROTENSINS; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 84866026108     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2011.00282.x     Document Type: Article

References (20)

1. Ames RS, Sarau HM, Chambers JK, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999;401:282-286.
2. Bern HA, Lederis K. A reference preparation for the study of active substances in the caudal neurosecretory system of teleosts. J Endocrinol 1969;45(Suppl):xi-xii.
3. Douglas SA, Tayara L, Ohlstein E, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 2002;359:1990-1997.
4. Russell FD, Meyers D, Galbraith AJ, et al. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 2003;285:H1576-H1581.
5. Nakayama T, Hirose T, Totsune K, et al. Increased gene expression of urotensin II-related peptide in the hearts of rats with congestive heart failure. Peptides 2008;29:801-808.
6. Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci 2003;104:1-5.
7. Tran L, Kompa AR, Kemp W, Phrommintikul A, Wang BH, Krum H. Chronic urotensin-II infusion induces diastolic dysfunction and enhances collagen production in rats. Am J Physiol Heart Circ Physiol 2010;298:H608-H613.
8. Loirand G, Rolli-Derkinderen M, Pacaud P. Urotensin II and atherosclerosis. Peptides 2008;29:778-782.
9. Watanabe T, Suguro T, Kanome T, et al. Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 2005;46:738-744.
10. Lim M, Honisett S, Sparkes CD, Komesaroff P, Kompa A, Krum H. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation 2004;109:1212-1214.
11. Sondermeijer B, Kompa A, Komesaroff P, Krum H. Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension. Am J Hypertens 2005;18(9 Pt 1):1195-1199.
12. Zomer E, de Ridder I, Kompa A, Komesaroff P, Gilbert R, Krum H. Effect of urotensin II on skin microvessel tone in diabetic patients without heart failure or essential hypertension. Clin Exp Pharmacol Physiol 2008;35:1147-1150.
13. Newman JW, Morisseau C, Hammock BD. Epoxide hydrolases: Their roles and interactions with lipid metabolism. Prog Lipid Res 1993;44:1-5.
14. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 1996;78:415-423.
15. Richards AM, Nicholls MG, Lainchbury JG, Fisher S, Yandle TG. Plasma urotensin II in heart failure. Lancet 2002;360:545-546.
16. Imig JD, Carpenter MA, Shaw S. The soluble epoxide hydrolase inhibitor AR9281 decreases blood pressure, ameliorates renal injury and improves vascular function in hypertension. Pharmceuticals 2009;2:217-227.
17. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 2002;39:690-694.
18. Jung O, Brandes RP, Kim I-H, et al. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 2005;45:759-765.
19. Li J, Carroll MA, Chander PN, Falck JR, Sangras B, Stier CT. Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension. Front Biosci 2008;13:3480-3487.
20. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 2000;275:40504-40510.